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Rubella in South Africa: An impending Greek tragedy? 
Barry D Schoub, Bernice N Harris, Jo McAnerney, Lucille Blumberg    
Rubella in children and adults is almost always a mild disease, 
with serious or long-term sequelae a rarity. The focus of 
concern is infection of susceptible women in the first 16 weeks 
of pregnancy. The risk of congenital rubella syndrome (CRS) 
in the first 8 - 10 weeks is up to 90%, after which it drops 
sharply and is virtually non-existent after 16 weeks other than 
rare mild systemic illnesses.1 The incidence of CRS globally 
has been estimated as between 0.1 and 0.2/1 000 live births 
in endemic periods and up to 1 - 4/1 000 live births following 
epidemics. The global toll of CRS is approximately 100 000 
cases per year.1 In practice, however, relatively few cases of 
CRS are reported and many are unrecognised, as the clinical 
manifestations may be delayed until months or even years after 
birth. Globally only 37 cases were reported to the World Health 
Organization (WHO) in 1995, none of them from South Africa.2 
Widespread use of rubella vaccine in the developed world 
has dramatically reduced the incidence of rubella and CRS. 
Soon after the vaccine became available in the early 1970s, 
many countries instituted vaccination programmes, targeting 
pre-adolescent girls at about 12 years of age before they 
become sexually active, to protect women when they reach 
childbearing age – so-called ‘selective immunisation’. These 
programmes, while moderately successful in protecting the 
group at risk, failed to influence the circulation of the virus, 
mainly because children are the major reservoir of infection, 
and the risk to unvaccinated or unsuccessfully vaccinated 
women remained. Approximately a decade later the strategy 
was changed to eliminate the circulation of wild-type rubella 
virus by routine immunisation of all children between 12 and 
15 months – so-called ‘universal immunisation’. High vaccine 
coverage rapidly brought about a dramatic reduction of the 
incidence of rubella, to the extent that the Pan American Health 
Organization (PAHO) has now targeted 2010 as the goal for 
the elimination of rubella from the Western hemisphere3 and 
the European region of the WHO has simultaneously set a 
goal of 2010 for that region.4 In these countries the problem of 
rubella and CRS is now confined to non-vaccinated immigrant 
populations. 
Rubella vaccine in contemporary use, RA27/3, is a safe 
effective vaccine, administered either as a monovalent vaccine 
or far more commonly in combination with measles (MR) or 
measles and mumps (MMR).1 Cost-benefit analyses in both 
developed and developing countries have shown ratios greater 
than 1.5 The impetus to introduce routine rubella immunisation 
is therefore great. MMR can also be given as effectively 
and safely at 9 months of age, when measles vaccination is 
routinely administered in many developing countries and 
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Background. The incidence of congenital rubella syndrome 
(CRS) is unknown in South Africa. There is evidence that it 
may be significant and largely undetected, particularly in the 
upper socio-economic group.  This may be due to incomplete 
routine administration of MMR vaccine in infancy and a 
build-up of susceptible females reaching the childbearing age 
group who could be exposed to the extensive reservoir of 
virus in the unimmunised public sector of the population.
Objective. To assess the extent of the immunity gap to rubella 
by testing for protective IgG antibodies and the incidence of 
rubella infection by testing for IgM antibodies in sera. The 
data obtained would also be used to model the extent of CRS. 
Design. Residual laboratory serum specimens from public and 
private laboratories were serologically tested for rubella IgG 
antibodies to investigate the immunity gap in the population 
and IgM antibodies in sera collected from the measles rash-
like illness surveillance programme. Modelling exercises 
calculated the force of infection and the predicted incidence of 
CRS in South Africa.
Results. The serological immunity gap was significantly 
greater in the private sector specimens compared with the 
public sector – 10.7% versus 5.4%, respectively. In most years 
rubella caused much more rash-like illness than measles, 
with a significant number (5.1 - 9.6%) of rubella-positive IgM 
specimens occurring in women of childbearing age.
Conclusion. Modelling of the data suggests that the extent 
of CRS may be grossly underestimated in South Africa. 
Approximately 654 cases are calculated to occur every year. 
It is suggested that selective immunisation of girls before 
puberty should be instituted together with a routine rubella 
immunisation programme of infants to forestall a possible 
future outbreak of CRS, as occurred in Greece in 1993.
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in South Africa.6 However, experiences in several countries 
have shown that hasty introduction of universal rubella 
vaccination (usually as MMR) before adequate precautionary 
conditions have been put into place (i.e. an extensive selective 
immunisation programme in place until adequate MMR 
vaccination coverage is achieved) may, paradoxically, greatly 
increase the risk of CRS.7 This is due to the potential for 
an upwards shift in age of rubella infection because of the 
reduction of wild-type virus circulation and its consequent 
reduction in population immunity, resulting in increasing 
numbers of vulnerable women in the childbearing age group 
susceptible to a still-present reservoir of circulating wild-type 
virus. 
In South Africa, a scenario could be building up similar 
to that in Greece in the 1990s before their unprecedented 
outbreak of CRS.7 Small but increasing use of MMR in the 
private sector may be building up a population of susceptible 
adolescents and young adults, while at the same time there is 
no programme for selective immunisation of girls. Indications 
are that the reservoir of the virus is large and could pose a 
serious threat for CRS.
South Africa has no programme for collecting data on 
clinically manifest CRS. We have attempted to model the 
theoretically expected extent of CRS and assess the potential 
risk for an outbreak of CRS.
Methods
Case-based surveillance
As part of the WHO programme to eliminate measles, all 
patients throughout South Africa presenting with a rash-
like illness with pyrexia and one of the symptoms coryza, 
conjunctivitis or cough have a specimen of blood taken to 
test for measles IgM. In addition, all specimens are tested at 
the National Institute for Communicable Diseases (NICD) for 
rubella IgM.
Serosusceptibility to rubella
Residual sera from laboratory specimens and banked sera were 
collected to assemble a range of samples from women of all 
ages and throughout all provinces of the country from both the 
private sector laboratories and the public sector through the 
National Health Laboratory Service (NHLS).
Serology
Sera were tested for the presence of rubella IgM antibodies 
(to indicate active infection) and IgG antibodies (to indicate 
immunity or susceptibility) using commercial EIA kits. 
Rubella-specific IgM was tested using the Dade Behring EIA kit 
and IgG antibodies using Biorad Platelia ELISA kit according to 
the manufacturer’s instructions. Rubella IgG levels  >15 IU/ml 
were interpreted as indicating immunity.
Statistical analysis
The Statistical Package for Social Sciences (SPSS) (version 13) 
was used for statistical evaluation. Significance of differences 
was determined using a one-way analysis of variance 
(ANOVA). Pearson’s correlation coefficient was determined 
within groups. Statistical significance was set at p-values <0.05.
Modelling methodology
To model the predicted incidence of CRS, data from the extent 
of rubella infection (IgG positive) and susceptibility data in 
women of childbearing age (12 - 49 years) were used. Age-
stratified seroprevalence data were used to construct a simple 
catalytic model in Excel to calculate the force of infection (FOI), 
as described by Cutts and Vynnycky.8 The average age of onset 
of infection, basic reproductive rate and level of coverage 
needed to achieve herd immunity was calculated from this FOI 
using a standard equation as described by Anderson and May.9
To estimate the number of congenital rubella syndrome 
cases for 2005, the methodology described by Cutts and 
Vynnycky8 was used to first estimate the incidence (force) of 
rubella infection assuming an age-dependent infection rate. 
The proportion of seronegative pregnant women was assumed 
to be identical to that of the general population. The estimated 
FOI for the population 15 years and older and the proportion 
of seronegative pregnant women was used to calculate the 
estimated incidence of infection during gestation, assumed to 
be 40 weeks.
The risk of CRS was calculated as the weighted average of 
risk after infection in pregnancy from data of Miller et al.10 as 
65% in the first 16 weeks and zero thereafter. The incidence of 
CRS per 100 000 live births was calculated by multiplying the 
proportion of live babies born to mothers first infected with 
rubella during the first trimester of pregnancy (identical to 
the cumulative incidence of rubella infection during the first 
16 weeks of pregnancy) by this risk. The potential for fetal 
loss following rubella infection is not accounted for in these 
calculations. Statistics South Africa’s 2005 mid-year estimate of 
the population under 1 year of age was used as a proxy for the 
number of pregnant women.
Results 
Patients presenting with a rash-like illness and clinically 
suspected measles were many times more likely to be IgM 
positive for rubella than for measles, except during the measles 
outbreak years of 2004 and 2005, and even in those years 
rubella positives exceeded measles positives (Table I). The 
seasonal distribution of rubella is shown in Fig. 1. The age 
distribution of IgM positives over the last 5 years is shown in 
Fig. 2 and ranges from 4 months to 64 years with a median of 
7 years. However, a significant number of positives were also 
found in women of childbearing age group – the proportion of 
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positive specimens in the age group 12 - 49 years, where age 
and gender were recorded, ranged from 5.1% in 2008 to 9.6% in 
2004 (Table II). 
A total of 8 940 samples were tested for rubella IgG 
antibodies (Table III). Of these, 1 295 were supplied by private 
laboratories, reflecting the higher socio-economic sector 
of the population, and 7 645 were public sector specimens 
from NHLS laboratories or banked serum specimens. The 
susceptibility gap (rubella IgG negative) for women 12 - 49 
years of age in private sector specimens was significantly 
greater that in public sector specimens (10.7% and 5.4% 
respectively; p<0.0005). The inter-provincial differences were 
insignificant.
The modelling exercise to predict the number of expected 
CRS cases in South Africa is shown in Table IV. During 2005 
there were projected to have been 69 CRS cases per 100 000 live 
births in South Africa, ranging from 16 per 100 000 live births 
in the Eastern Cape to 69 in the Free State. The confidence 
intervals for most estimates are wide except for Limpopo 
province and the South African total. On the basis of these 
estimates there may have been 654 cases in South Africa for 
that year. The expected yearly incidence of CRS will vary 
depending on the epidemic cycle of the area, i.e. more cases 
during a year with a larger epidemic. The variation in 
incidence between provinces may be an artefact of small 
numbers or due to provinces being at different stages of the 
rubella epidemic cycle.
Discussion 
Rubella vaccine is not a component of the routine 
immunisation policy of South Africa, despite its being safe, 
effective and readily added to measles vaccine at minimal  
extra cost.
Fig. 1. Seasonal distribution of rubella.
Table I.  Measles and rubella IgM positivity in individuals presenting with rash-like illness, 1999 - 2008
     Measles   Rubella   Females 12 - 49 yrs
Year     (pos./N (%))  (pos./N (%))  (pos./N* (%))
1998     24/529 (4.5)  188/529 (35.5)  4/100 (4.0)
1999     50/1 008 (5.0)  3 68/1 008 (36.5)  13/300 (4.3)
2000     31/938 (3.3)  372/746 (49.9)  17/341 (5.0)
2001     6/893 (0.7)  383/766 (50.0)  25/362 (9.7)
2002     6/817 (0.7)  280/817 (34.3)  16/254 (6.3)
2003     209/3 940 (5.3)  1 880/3 940 (47.7)  94/1 717 (5.5)
2004     726/3 301 (22.0)  851/3 301 (25.8)  76/790 (9.6)
2005     697/4 372 (15.5)  1 031/4 372 (23.6)  84/898 (9.4)
2006     82/6 661 (1.2)  2 982/6 661 (44.8)  212/2 586 (8.2)
2007     30/3 252 (0.9)  1 078/3 252 (33.1)  66/971 (6.8)
2008     28/2 787 (1.0)  1 071/2 787 (38.4)  45/1 025 (4.4)
*Where age and sex were known.
Pos. = number positive; N = number tested.
Table II.  Proportion of females of childbearing age (12 - 49 
years) positive for rubella IgM where age and gender are 
known
     Total with age and 
Year      gender recorded  Females               %
2004  790      76              9.6
2005  898      84              9.4
2006  2 586      212              8.2
2007  971      66              6.8
2008  468      24              5.1
Figure 2: Age distribution of patients with rubella: 2003-2008
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Fig. 2. Age distribution of patients with rubella, 2003 - 2008.
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The annual incidence of CRS in South Africa is unknown 
– it is rarely diagnosed by clinicians. By modelling data 
collected from nationwide serological studies, we predict that 
there should be approximately 654 cases of CRS per year in 
South Africa, i.e. approximately 0.5/1 000 live births, a figure 
considerably higher than the WHO estimated figure of 0.1 - 0.2 
in endemic periods but lower than the epidemic rates of 1 - 4 
per 1 000 live births.1 Most CRS cases may well not manifest at 
birth, and physical, intellectual and developmental retardation 
or auditory or visual problems appearing later in life may 
well not be ascribed to CRS. Surveillance of CRS requires 
active programmes, which have been carried out in several 
developing countries, such as a congenital cataracts survey 
in India11 and clinical-virological surveillance in Myanmar.12 
Similar studies, for example newborn hearing screening,13 need 
to be undertaken to determine the true incidence of CRS in 
South Africa.
Nevertheless, data from studies in South Africa and our 
recent serosurveillance study reported above indicate that a 
significant sero-immunity gap (i.e. an absence of detectable 
protective IgG antibodies) exists in the upper socio-economic 
sector of the population, with some 10% of women whose 
sera were tested in private laboratories being seronegative as 
opposed to 5% for public sector specimens. Similar findings 
of a 5 - 7% serological gap were reported in public sector sera 
from the Western Cape,14 Johannesburg15 and Maputo.16 The 
worryingly wide sero-immunity gap in women from upper 
socio-economic strata was also evident in several studies 
published from Cape Town (10 - 18% in hospital staff)17,18 and 
Johannesburg (10 - 18.4% in laboratory staff and students).15 
The immunity gap in upper socio-economic group 
women largely reflects better living standards and less 
crowding. However, the influence of the small but significant 
administration of MMR by private vaccination clinics may 
well aggravate the situation. Some 58 800 doses of MMR 
were administered over a 12-month period in 2007/2008. We 
estimate that about 100 000 children per annum utilise private 
vaccination facilities (about two-thirds of the 14.7% of the 
population who are on a medical aid), giving estimated rubella 
coverage of approximately 59%. This could be enough to 
reduce the circulation of wild-type virus sufficiently to create a 
significant immunity gap in adolescent and young women in 
Table III. Specimens positive for rubella IgG per province and health sector, 2005/2006 
   Children younger than 12 years of age   Women 12 years of age and older
Province            Total            Pos. % pos.   Total           Pos. % pos.
Eastern Cape           228              135 59.2   603           576  95.5
Free State            135              64 47.4   250           240  96.0
Gauteng            427              247 57.8   739           700  94.7
KwaZulu-Natal           74              41 55.4   379           360  95.0
Limpopo            47              24 51.1   3 318           3 142 94.7
Mpumalanga           304              206 67.8   341           312  91.5
Northern Cape           16              7  43.8   79           73  92.4
North West           174              86 49.4   303           285  94.1
Western Cape           16              8  50.0   212           202  95.3
Public sector           1 421            818 57.6   6 224           5 890 94.6
Private sector           89              56 62.9   1 206           1 077 89.3
   Total            1 510            874 57.9   7 430           6 967 93.8
Table IV.  Modelling congenital rubella syndrome
      Incidence of rubella 
     infection per 100 000          Incidence of rubella      Incidence of
      Proportion   pregnancies at age         infection per 100 000    CRS per 100 000
         Population    seronegative       15 - 44 years             in first trimester        live births     No. of CRS
Province      <1 year, 2005   in pregnancy      (mean (95 Cl))               (mean (95 Cl))      (mean (95 Cl))    (mean (95 Cl))
Eastern Cape       112 355        0.042        62        (0 - 188)              25           (0 - 76)      16        (0 - 49)    18        (0 - 56)
Free State               56 914        0.038      345     (154 - 607)            142        (62 - 256)      92    (40 - 166)    53      (23 - 95)
Gauteng             188 903        0.052      270     (139 - 423)            110        (56 - 174)      71    (36 - 113)  135     (69 - 213)
KwaZulu-Natal   202 615        0.046      129        (0 - 304)              52          (0 - 124)      34        (0 - 81)    69      (0 - 164)
Limpopo              117 851        0.051      322     (267 - 382)            132      (108 - 156)      85    (71 - 102)  101     (83 - 120)
Mpumalanga         79 069        0.082       86        (0 - 324)              35         (0 - 131)      22        (0 - 85)    18        (0 - 67)
North West            82 021        0.050     194      (24 - 415)              78         (9 - 170)      51      (6 - 111)    42        (5 - 91)
Northern Cape      15 564        0.056     291    (150 - 457)            118       (60 - 187)      77    (39 - 122)    12        (6 - 19)
Western Cape        94 179        0.047     245    (126 - 384)              99        (51 - 158)      65    (33 - 102)    61      (31 - 97)
   Total              949 471        0.051     261    (220 - 267)            106        (89 - 124)      69      (58 - 81)  654   (549 - 766)
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this population. The scenario of rubella vaccination not being 
part of public policy but given in the private sector is common 
to many developing countries. The impact of private sector 
MMR vaccination has been modelled mathematically.19 The 
risk for the development of CRS was shown to be determined 
by three factors: (i) the pre-vaccination force of infection; (ii) 
the extent of private vaccination; and (iii) random mixing 
between the two populations. In South Africa the FOI is high, 
as shown by the large numbers of rubella IgMs detected 
in the rash surveillance programme as well as the high 
seroprevalence in women from the public sector. The extent of 
private vaccination is high in the urbanised population, where 
extensive mixing is also a feature. These factors suggest that 
the endemic incidence of CRS may well be considerable, while 
the risk of CRS were a large-scale epidemic to occur would be 
much greater. Fig. 1 illustrates the seasonal curve of rubella in 
South Africa. Although data before 2007 are very incomplete, 
the curve suggests increased epidemic activity every 2 - 3 
years, a feature typical of rubella in temperate climates in the 
pre-vaccination era.20 If this pattern is followed, in the year 
2009 (spring/early summer) we may well see an upsurge in 
rubella and possibly an outbreak of CRS.
The temptation to rush into incorporating MMR into the 
routine immunisation programme should be resisted until 
adequate protective conditions have been put into place to 
prevent an upward age shift of infection. The tragic outbreak 
of CRS in Greece is a graphic example of what could happen if 
MMR is introduced into routine immunisation without other 
programmes being in place.7 MMR immunisation of 15-month-
old infants was introduced in the private sector in Greece in 
1975, achieving coverage of just under 50% during the 1980s. 
In 1989 it was introduced into the public sector for 15-month-
old infants and in 1991 changed to a 2-dose schedule at ages 
15 months and 11 years. Importantly, there was no selective 
immunisation programme in place for adolescent girls. A study 
of outpatient rubella cases showed a significant shift in the 
age of infection from a median of 7 years in 1988 to 15 years 
in 1993. The percentage susceptibility in pregnant women 
similarly rose from 11% in 1971/5 to 35% in 1990/1. A large 
outbreak of rubella in the early spring of 1993 was followed 
later that year by the largest outbreak of CRS ever recorded in 
that country – 24 CRS cases per 1 000 live births.
CRS can and should be eliminated from South Africa by 
simply making MMR part of routine immunisation. However, 
rushing into this without adequate safeguards may result in 
more harm than good. Before routine MMR is contemplated 
the following two precautionary conditions must be met:
•    A robust programme for selective immunisation of pre-
pubertal/adolescent girls, best achieved by making 
immunisation a critical component of the school health 
system. This would also allow for other important 
adolescent vaccinations such as Td (tetanus and reduced-
dose diphtheria vaccines), aP (acellular pertussis vaccine) 
and measles, and in future HPV and later HIV.
•    Routine measles immunisation coverage needs to be 
strengthened. A sustained coverage of >80% (the figure for 
the measles vaccine currently used, which is indicative of 
what the coverage would be if the combined MMR were to 
be introduced) in all districts is required in order to effect 
the reduction of circulating virus.1
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